Announced
Financials
Tags
Pharmaceuticals
Acquisition
Domestic
Friendly
Majority
vaccine development
France
Pending
Private
Single Bidder
Synopsis
Substipharm, a privately held pharmaceutical group, agreed to acquire IMOJEV, a Japanese encephalitis vaccine, from Sanofi, a French multinational pharmaceutical company. Financial terms were not disclosed. “This acquisition provides a massive breakthrough for Substipharm entering a new therapeutic area and reaching new geographies across Asia Pacific. Prevention is a strategic focus for our company, and we aspire to be a recognized partner for vaccines in the long term. This vaccine protects people and saves lives against a disease for which there is currently no curative treatment. With IMOJEV®, Substipharm is taking another step forward to support its rapid growth pattern outside Europe," Leopold Berthier, Substipharm CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.